Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1995 1
1997 2
1999 1
2000 2
2001 3
2002 5
2003 2
2004 1
2005 5
2006 9
2007 7
2008 11
2009 10
2010 7
2011 6
2012 6
2013 2
2014 5
2015 3
2016 11
2017 4
2018 7
2019 9
2020 7
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

109 results
Results by year
Filters applied: . Clear all
Page 1
Current and future pharmacological therapies for NAFLD/NASH.
Sumida Y, Yoneda M. Sumida Y, et al. J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16. J Gastroenterol. 2018. PMID: 29247356 Free PMC article. Review.
This class of drug includes apoptosis signaling kinase 1 (ASK1) inhibitor and emricasan (an irreversible caspase inhibitor). A third target is intestinal microbiomes and metabolic endotoxemia. Several agents are in ongoing trials, including IMMe124, TLR4 antagonist, and so …
This class of drug includes apoptosis signaling kinase 1 (ASK1) inhibitor and emricasan (an irreversible caspase inhibitor). A third target …
Molecular basis for intestinal mucin recognition by galectin-3 and C-type lectins.
Leclaire C, Lecointe K, Gunning PA, Tribolo S, Kavanaugh DW, Wittmann A, Latousakis D, MacKenzie DA, Kawasaki N, Juge N. Leclaire C, et al. FASEB J. 2018 Jun;32(6):3301-3320. doi: 10.1096/fj.201700619R. Epub 2018 Jan 29. FASEB J. 2018. PMID: 29401627 Free PMC article.
We used a combination of structural, biochemical, biophysical, and cell-based approaches to decipher the specificity of the interaction between mucin glycans and mammalian lectins expressed in the gut, including galectin (Gal)-3 and C-type lectin receptors. Gal-3
We used a combination of structural, biochemical, biophysical, and cell-based approaches to decipher the specificity of the interaction betw …
Pleiotropic Effects of Modified Citrus Pectin.
Eliaz I, Raz A. Eliaz I, et al. Nutrients. 2019 Nov 1;11(11):2619. doi: 10.3390/nu11112619. Nutrients. 2019. PMID: 31683865 Free PMC article. Review.
Modified citrus pectin (MCP) has a low-molecular-weight degree of esterification to allow absorption from the small intestinal epithelium into the circulation. MCP produces pleiotropic effects, including but not limited to its antagonism of galectin-3, which …
Modified citrus pectin (MCP) has a low-molecular-weight degree of esterification to allow absorption from the small intestinal epithe …
Galectin-3 regulates desmoglein-2 and intestinal epithelial intercellular adhesion.
Jiang K, Rankin CR, Nava P, Sumagin R, Kamekura R, Stowell SR, Feng M, Parkos CA, Nusrat A. Jiang K, et al. J Biol Chem. 2014 Apr 11;289(15):10510-7. doi: 10.1074/jbc.M113.538538. Epub 2014 Feb 24. J Biol Chem. 2014. PMID: 24567334 Free PMC article.
The desmosomal cadherins, desmogleins, and desmocollins mediate strong intercellular adhesion. Human intestinal epithelial cells express the desmoglein-2 isoform. A proteomic screen for Dsg2-associated proteins in intestinal epithelial cells identified a lectin refe …
The desmosomal cadherins, desmogleins, and desmocollins mediate strong intercellular adhesion. Human intestinal epithelial cells expr …
Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.
Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S. Ajani JA, et al. Br J Cancer. 2018 Jan;118(1):52-61. doi: 10.1038/bjc.2017.388. Epub 2017 Nov 14. Br J Cancer. 2018. PMID: 29136404 Free PMC article.
BACKGROUND: Overexpression of Galectin-3 (Gal-3), a beta-galactoside binding protein, has been noted in many tumour types but its functional significance and clinical utility in gastric adenocarcinoma (GAC) are not well known. METHODS: We studied 184 G …
BACKGROUND: Overexpression of Galectin-3 (Gal-3), a beta-galactoside binding protein, has been noted in many tumour typ …
Matrilysin-1 (MMP7) cleaves galectin-3 and inhibits wound healing in intestinal epithelial cells.
Puthenedam M, Wu F, Shetye A, Michaels A, Rhee KJ, Kwon JH. Puthenedam M, et al. Inflamm Bowel Dis. 2011 Jan;17(1):260-7. doi: 10.1002/ibd.21443. Epub 2010 Sep 1. Inflamm Bowel Dis. 2011. PMID: 20812334 Free PMC article.
The aim was to determine whether MMP7 cleaves galectin-3 and modulates wound healing in intestinal epithelial cells. ...This study has significance in understanding delayed wound healing in chronic intestinal diseases like intestinal ulcers
The aim was to determine whether MMP7 cleaves galectin-3 and modulates wound healing in intestinal epithelial cells. .. …
Lack of galectin-3 involvement in murine intestinal nematode and schistosome infection.
Bickle Q, Helmby H. Bickle Q, et al. Parasite Immunol. 2007 Feb;29(2):93-100. doi: 10.1111/j.1365-3024.2006.00923.x. Parasite Immunol. 2007. PMID: 17241397 Free article.
Here we show that galectin-3 is not involved in the development of the Th2 response nor in schistosome granuloma formation. Galectin-3-deficient mice were able to expel the gastrointestinal nematode Trichuris muris at the same speed as wild-type mice. …
Here we show that galectin-3 is not involved in the development of the Th2 response nor in schistosome granuloma formation. …
Galectin-3 modulates T cell activity and is reduced in the inflamed intestinal epithelium in IBD.
Müller S, Schaffer T, Flogerzi B, Fleetwood A, Weimann R, Schoepfer AM, Seibold F. Müller S, et al. Inflamm Bowel Dis. 2006 Jul;12(7):588-97. doi: 10.1097/01.MIB.0000225341.37226.7c. Inflamm Bowel Dis. 2006. PMID: 16804396
The present study aims to determine galectin-3 expression in the normal and inflamed intestinal mucosa and to define its role in T cell activity. ...Therefore, galectin-3 may prove valuable for manipulating disease activity....
The present study aims to determine galectin-3 expression in the normal and inflamed intestinal mucosa and to define it …
Galectin-3 as a Therapeutic Target for NSAID-Induced Intestinal Ulcers.
Park AM, Khadka S, Sato F, Omura S, Fujita M, Hsu DK, Liu FT, Tsunoda I. Park AM, et al. Front Immunol. 2020 Sep 23;11:550366. doi: 10.3389/fimmu.2020.550366. eCollection 2020. Front Immunol. 2020. PMID: 33072090 Free PMC article.
Non-steroidal anti-inflammatory drugs (NSAIDs) induce ulcers in the gastrointestinal tract, including the stomach and small intestine. ...Galectin-3 (Gal3), an endogenous lectin, has anti-microbial and pro-inflammatory functions. ...
Non-steroidal anti-inflammatory drugs (NSAIDs) induce ulcers in the gastrointestinal tract, including the stomach and small …
Mucins and mucin binding proteins in colorectal cancer.
Byrd JC, Bresalier RS. Byrd JC, et al. Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99. doi: 10.1023/a:1025815113599. Cancer Metastasis Rev. 2004. PMID: 15000151 Review.
There are, however, cancer-associated increases in sialyl LeX and related structures on mucins and other glycoproteins that can serve as ligands for selectins, increasing the metastatic capacity of colon cancer cells. The endogenous galactoside-binding protein galectin- …
There are, however, cancer-associated increases in sialyl LeX and related structures on mucins and other glycoproteins that can serve as lig …
109 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback